We did not evaluate the effect of panitumumab or cetuximab treatment after tumors achieved distant metastases, so the predictive value of BRAF mutation for monoclonal antibody treatment in stage IV CRC patients was unexplored. Here, BRAF is linked to colorectal carcinoma.